HomeCompareHNHPF vs ABBV

HNHPF vs ABBV: Dividend Comparison 2026

HNHPF yields 3.23% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $9.4K in total portfolio value
10 years
HNHPF
HNHPF
● Live price
3.23%
Share price
$11.98
Annual div
$0.39
5Y div CAGR
38.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$93.0K
Annual income
$27,927.47
Full HNHPF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — HNHPF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHNHPFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HNHPF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HNHPF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HNHPF
Annual income on $10K today (after 15% tax)
$274.40/yr
After 10yr DRIP, annual income (after tax)
$23,738.35/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, HNHPF beats the other by $2,682.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HNHPF + ABBV for your $10,000?

HNHPF: 50%ABBV: 50%
100% ABBV50/50100% HNHPF
Portfolio after 10yr
$97.7K
Annual income
$26,349.61/yr
Blended yield
26.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HNHPF
No analyst data
Altman Z
3.0
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HNHPF buys
0
ABBV buys
0
No recent congressional trades found for HNHPF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHNHPFABBV
Forward yield3.23%3.06%
Annual dividend / share$0.39$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR38.6%40.6%
Portfolio after 10y$93.0K$102.3K
Annual income after 10y$27,927.47$24,771.77
Total dividends collected$65.8K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HNHPF vs ABBV ($10,000, DRIP)

YearHNHPF PortfolioHNHPF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,147$447.43$11,550$430.00$403.00ABBV
2$12,574$646.07$13,472$627.96$898.00ABBV
3$14,398$943.96$15,906$926.08$1.5KABBV
4$16,806$1,400.12$19,071$1,382.55$2.3KABBV
5$20,099$2,116.93$23,302$2,095.81$3.2KABBV
6$24,786$3,279.46$29,150$3,237.93$4.4KABBV
7$31,759$5,238.45$37,536$5,121.41$5.8KABBV
8$42,677$8,694.61$50,079$8,338.38$7.4KABBV
9$60,798$15,134.00$69,753$14,065.80$9.0KABBV
10$92,982$27,927.47$102,337$24,771.77$9.4KABBV

HNHPF vs ABBV: Complete Analysis 2026

HNHPFStock

Hon Hai Precision Industry Co., Ltd. provides technology solutions in Japan, Ireland, the United States, Singapore, China, Taiwan, and internationally. The company manufactures, sells, and services connectors, cases, thermal modules, wired/wireless communication products, optical products, power supply modules, and assemblies for use in the information technology, communications, automotive equipment, precision molding, automobile, and consumer electronics industries. It also manufactures and sells computer terminal monitors and related components, as well as data storage and processing equipment; offers solutions for autonomous driving systems, new energy power, and IoV systems; and provides services of planning, advisory, and business operation and management, logistics, export processing, construction, leasing, and information/software services. In addition, the company manufactures and sells application modules and network cables assemblies; develops educational technology; holds patent applications; manufactures and trades in portable cameras; and retails office machinery and equipment, and electronic appliances. Further, it is involved in the reinvestment in the businesses relating to robots, automatic equipment, molds, parts, and accessories and corresponding services; and software development, repair and after-sale, and rental services of robots. Additionally, the company manufactures and sells computer and data processing equipment, WIFI cards and modules, CFTVs, DVRs, Bluetooth modules, set-top boxes, and optical network terminals. It is also involved in the provision of data storage services; manufacturing of wire or wireless communication; installation of computer and satellite TV channels; and provision of mobile phone services, as well as telecom-related business. The company was founded in 1974 and is headquartered in New Taipei City, Taiwan.

Full HNHPF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HNHPF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HNHPF vs SCHDHNHPF vs JEPIHNHPF vs OHNHPF vs KOHNHPF vs MAINHNHPF vs JNJHNHPF vs MRKHNHPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.